Promising Outcomes from First-in-Human Trial of DLL3-Targeted Antibody-Drug Conjugate SHR-4849 in Relapsed Small Cell Lung Cancer
In a landmark development in the treatment of relapsed small cell lung cancer (SCLC), scientists have unveiled promising results from ...

